statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of AnaptysBio, Inc. (NASDAQ:ANAB - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the seven analysts that are covering the stock, Marketbeat Ratings...

AnaptysBio, Inc. (NASDAQ:ANAB) Receives Average Recommendation of "Moderate Buy" from Analysts

AnaptysBio (NASDAQ:ANAB - Free Report) had its price target trimmed by JPMorgan Chase & Co. from $30.00 to $28.00 in a report issued on Monday, Benzinga reports. The firm currently has a neutral...

AnaptysBio (NASDAQ:ANAB) Given New $28.00 Price Target at JPMorgan Chase & Co.

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

AnaptysBio price target lowered by $2 at JPMorgan, here's why

AnaptysBio, Inc. (NASDAQ:ANAB  Get Free Report) CEO Daniel Faga sold 145,940 shares of the businesss stock in a transaction dated Friday, March 22nd. The shares were sold at an average...

Insider Selling: AnaptysBio, Inc. (NASDAQ:ANAB) CEO Sells $3,324,513.20 in Stock

AnaptysBio, Inc. (NASDAQ:ANAB  Get Free Report) CEO Daniel Faga sold 3,000 shares of the stock in a transaction dated Monday, March 25th. The shares were sold at an average price of $21.42...

AnaptysBio, Inc. (NASDAQ:ANAB) CEO Sells $64,260.00 in Stock

This price move could indicate a change in the trend, and may be a sell signal for investors...

AnaptysBio (ANAB, $21.67) price exceeded its 50-day Moving Average on March 22, 2024

This price move could be a signal that ANAB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options...

AnaptysBio (ANAB, $21.67) price may climb as it broke lower Bollinger Band on Mar 22, 2024

This is a signal that ANAB's price trend could be reversing, and it may be an opportunity to buy the stock or explore call options...

AnaptysBio (ANAB, $21.67) Stochastic Oscillator left the oversold zone on March 22, 2024

This price move could indicate a change in the trend, and may be a buy signal for investors...

AnaptysBio (ANAB, $24.45) price moved above its 50-day Moving Average on March 21, 2024

ANAB's total volume now sits at 312.8K. The +-0.85% price change was insignificant, leaving IBM's price at $23.45...

The volume for AnaptysBio stock increased for one day, resulting in a record-breaking daily growth of 320% of the 65-Day Volume Moving Average

AnaptysBio, Inc. is a clinical stage biotechnology company. engages in the development of antibody product candidates. Its products pipeline include ANB030, ANB030, and Imsidolimab. It also offers SHM platform that replicate the natural process of somatic hypermutation embedded within the human immune system to rapidly develop a diverse range of therapeutic-grade antibodies in vitro. The company was founded by Andrew B. Cubitt, William J. Boyle, Kevin J. Kinsella, and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.

Volume	331,954.00
52-Wk High	$27.50
52-Wk Low	$13.36

Period	Estimated	Reported	Surprise	Result
Q1'24	-$1.57	--	--	N/A
Q4'23	-$1.60	-$1.59	0.67%	BEAT
Q3'23	-$1.78	-$1.41	20.65%	BEAT
Q2'23	-$1.70	-$1.50	11.53%	BEAT
Q1'23	-$1.03	-$1.58	-53.09%	MISSED

ANAB AnaptysBio Inc

About

Feed

News

Sentiment

Earnings

Fundamentals